Manipulating Immune Responses with Immunosuppressive Agents that Target NFAT  by Kiani, Alexander et al.
Immunity, Vol. 12, 359±372, April, 2000, Copyright ª 2000 by Cell Press
Manipulating Immune Responses Review
with Immunosuppressive Agents
that Target NFAT
iting a remarkable gain of function relative to the drugs
themselves (Schreiber and Crabtree, 1992).
In the immune system, calcineurin and NFAT, the ma-
jor targets of CsA and FK506, regulate the expression
of a large number of inducible genes encoding cytokines
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³Department of Pathology ductive immune response (Rao et al., 1997). Some of
Harvard Medical School and the immunosuppressive effects of CsA may depend on
The Center for Blood Research its ability to induce TGFb, an immunosuppressive cyto-
Boston, Massachusetts 02115 kine, in diverse cells and tissues (Suthanthiran et al.,
1996). CsA or FK506 are frequently used in combination
with less specific immunosuppressants such as predni-
The immune system is a complex network of cellular sone, azathioprine, methotrexate, and mycophenolate
and humoral factors that ensures the integrity of the mofetil to achieve synergistic immunosuppressive ef-
organism by attacking potential pathogens. Sometimes fects (Suthanthiran et al., 1996; Gummert et al., 1999).
this normally protective system overreacts and directs The main drawback of these immunosuppressive regi-
its forces at the organism itself. The clinical syndrome mens, however, is that they produce major toxic side
of septic shock results from overactive host responses effects and therefore are rarely employed except in seri-
to gram-negative bacterial infections and can be fatal ous clinical situations.
because of an overwhelming production of proinflam- Our thesis in this review is that since NFAT is a vali-
matory cytokines. Transplantation of solid organs is dated target for two clinically important immunosup-
confounded by the immunologic problem of graft rejec- pressive drugs, interference with NFAT regulation might
tion, while graft-versus-host-disease is one of the major be expected to yield additional avenues for immunosup-
complications of transplantation with allogeneic bone pression. Moreover, since NFAT is only one of many
marrow or peripheral blood stem cells, severely limiting calcineurin substrates, compounds that interfere selec-
the application of these potentially life-saving therapeu- tively with NFAT regulation might be expected to have
tic options. Other examples of inappropriate immune fewer side effects than CsA and FK506. Unfortunately,
responses include allergic asthma and chronic autoim- this simple premise is complicated by the existence of
mune diseases such as rheumatoid arthritis. A major multiple NFAT proteins, our incomplete knowledge of
challenge for clinicians is how to suppress deleterious their regulation and function in immune and nonimmune
immune responses in these diverse clinical settings. cells, and our lack of information about the mechanisms
The fungal metabolites cyclosporin A (CsA) and tacrol- underlying the toxic effects of CsA and FK506.
imus (FK506) are among the most potent immunosup- Here we review our current understanding of these
pressive drugs available today. CsA revolutionized the points. We consider what features of NFAT regulation
field of organ transplantation following its discovery in might be exploited to develop selective inhibitors of
1976 (Borel et al., 1976); it was approved for clinical use NFAT, whether such drugs would be as immunosup-
in 1983. Tacrolimus was described soon after (Kino et pressive as CsA or FK506, whether they would lack the
al., 1987) and introduced into clinical trials in 1989. De- toxic effects of CsA and FK506, and whether they might
spite their lack of structural similarity, the modes of have unexpected side effects in immune and nonimmune
action of these two drugs are very similar: at the low organs. An informed understanding of these issues might
concentrations relevant to their immunosuppressive ef- spur the development of better, less toxic immunosup-
fects, they inhibit the calcium-dependent serine/threo- pressive agents that target the NFAT pathway.
nine phosphatase calcineurin and its substrate, the tran-
scription factor NFAT (Schreiber and Crabtree, 1992).
The drugs do not interact directly with calcineurin but What Features of NFAT Regulation Might Be Exploited
rather form complexes with intracellular receptors known to Develop Selective Inhibitors of NFAT?
as immunophilins. The immunophilin receptors for cyclo- The NFAT family, consisting of the ªclassicalº members
sporin A are the cyclophilins, while those for FK506 are NFAT1 (p, c2), NFAT2 (c, c1), NFAT3 (c4), and NFAT4
the FK506-binding proteins (FKBPs). Both classes of (x, c3), has recently been extended by a fifth member,
immunophilin receptors are widely expressed, abundant NFAT5/TonEBP (Table 1) (Lopez-Rodriguez et al., 1999;
enzymes possessing peptidyl-prolyl isomerase activity, Miyakawa et al., 1999). NFAT5 differs from the other
which function as protein chaperones within the cell
NFAT proteins in being regulated by osmotic shock
(Schreiber and Crabtree, 1992). It is the drug-immunoph-
rather than calcineurin. Here we consider only the cal-
ilin complexes that bind calcineurin and inhibit its phos-
cineurin-regulated family members NFAT1±4. For sim-
phatase activity toward peptide substrates, thus exhib-
plicity, we use the term NFAT to refer to these four
proteins, unless specific distinctions are being drawn.§ To whom correspondence should be addressed (e-mail: arao@
In the following sections, we describe different aspectscbr.med.harvard.edu).
of NFAT regulation, emphasizing basic features com-k Present address: Facultat de CieÁ ncies de la Salut i la Vida, Universi-
tat Pompeu Fabra, 08003 Barcelona, Spain. mon to all the proteins and indicating the possibility of
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Table 1. The NFAT Family
Present in
NFAT Protein Immune Cells? Other Features Phenotype of Knockout Mice
NFAT1 (p, c2) Yes 80%±90% of total NFAT Increased IL-4 production, Th2 bias
in resting immune cells (delayed shutoff of IL-4 transcription)
NFAT2 (c, c1) Yes One isoform induced Embryonic lethality (heart valve defect)
upon activation Lymphocytes produce less IL-4
NFAT3 (c4) No Implicated in cardiac Viable and fertile
hypertrophy Detailed phenotype not reported yet
NFAT4 (x, c3) Yes Highly expressed Defect in positive selection
in thymocytes of thymocytes
NFAT5 (TonEBP) Yes Nuclear, not cytoplasmic Knockouts not available yet
Not calcineurin-regulated NFAT5 is not implicated in the regulation
Does not cooperate with Fos/Jun of conventional NFAT target genes
subtype-specific regulation where appropriate (Figures by calcineurin; translocation to the nucleus; potentially,
activation by posttranslational modifications in the nu-1 and 2).
Overview cleus; binding to regulatory elements of NFAT target
genes; and interactions with nuclear proteins. Together,The general features of NFAT regulation have recently
been reviewed (Crabtree, 1999). NFAT proteins are regu- these steps are necessary for the incorporation of NFAT
into a transcriptionally active enhanceosome complexlated by a reversible cycle of dephosphorylation and
rephosphorylation (Figure 1). NFAT becomes activated at the promoter/enhancer regions of NFAT-dependent
genes. Sustained calcineurin activity is needed to main-when cells are stimulated through receptors coupled
to phospholipase C. The resulting rise in intracellular tain NFAT in an activated state; when calcium levels
drop or when calcineurin is inactivated, for instance bycalcium levels triggers the activation of calcineurin and
other calmodulin-dependent enzymes. NFAT activation removing the stimulus, inhibiting capacitative calcium
entry, or treating cells with CsA or FK506, NFAT is rapidlycan be considered in several steps: dephosphorylation
Figure 1. The NFAT Activation Cycle
In resting cells, NFAT resides in the cyto-
plasm, where it is maintained in a phosphory-
lated state by the action of constitutive ki-
nases. Stimulation of cell surface receptors
coupled to phospholipase C (PLC) results in
calcium mobilization and activation of the
phosphatase calcineurin. Calcineurin dephos-
phorylates NFAT, triggering its nuclear trans-
location and enhancing its DNA binding and
transcriptional activity. In the nucleus, NFAT
interacts with transcription factors (TFs) and
coactivators, stimulating gene expression.
When calcium levels drop, calcineurin be-
comes inactive, and NFAT is rephosphory-
lated by constitutive or inducible kinases and
exported back to the cytoplasm. The immu-
nosuppressive drugs cyclosporin A (CsA) and
FK506 inhibit calcineurin and prevent the ex-
pression of NFAT target genes. The green
boxes indicate the enzymes and processes
that maintain NFAT in a transcriptionally ac-
tive state. Numbers indicate points of poten-
tial intervention in the NFAT pathway.
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rephosphorylated and exported from the nucleus (Loh block the CsA-sensitive induction of the TNFb and LTb
genes (Aramburu et al., 1998, 1999).et al., 1996a, 1996b; Shibasaki et al., 1996; Timmerman
et al., 1996). At least one isoform of NFAT2 is regulated, These results are promising in terms of developing
pharmacological inhibitors selective for NFAT. They im-in addition, by a calcium- and calcineurin-dependent
induction of its mRNA in activated T cells (Northrop et ply that it should be possible to identify small molecule
inhibitors of the NFAT-calcineurin interaction that doal., 1994; Chuvpilo et al., 1999). Hence, NFAT's activation
state is the overall result of a balance between multiple not interfere with calcineurin phosphatase activity and
therefore would target selectively the ability of cal-regulatory processes, which could all be potential tar-
gets of therapeutic intervention (Figure 1). These pro- cineurin to dephosphorylate NFAT. Such selective NFAT
inhibitors would be expected to have fewer side effectscesses are identified by numbers in Figure 1 and cross-
referenced to the sections below. than generalized inhibitors of calcineurin and would also
be expected to lack any calcineurin-independent toxicCapacitative Calcium Entry (1)
Sustained calcium mobilization appears essential for effects of CsA or FK506. Potential calcineurin-indepen-
dent effects include, for instance, those arising from theproductive NFAT activation. Release of calcium from
intracellular stores may trigger some early dephosphor- ability of CsA and FK506 to inhibit the peptidyl-prolyl
isomerase activities, and therefore the chaperone func-ylation and nuclear entry of NFAT, but this is not sus-
tained in the absence of capacitative (store-operated) tions, of their respective immunophilin receptors (Schrei-
ber and Crabtree, 1992).calcium entry through CRAC channels (Negelscu et al.,
1994; Dolmetsch et al., 1997). Jurkat T cells selected A caveat of PxIxIT-based inhibitors, however, is that
they might inhibit dephosphorylation or function of otherfor impaired NFAT activation showed varying levels of
impaired calcium mobilization as their major signaling calcineurin binding proteins that used a similar docking
sequence or bound the same calcineurin surface asdefect (Fanger et al., 1995). NFAT also monitors the
frequency of calcium oscillations in cells (Dolmetsch et NFAT. So far there is only one known mammalian protein
that contains a clear PxIxIT-related sequence (PEITVT)al., 1998; Li et al., 1998). Oscillations of physiological
frequency are much more effective than lower frequency in its calcineurin binding domain: the nuclear cal-
cineurin-interacting protein Cabin-1/Cain-1 (Sun et al.,oscillations, consistent with rapid deactivation of both
calcineurin and NFAT upon cessation of the calcium 1998; Lai et al., 1998). While this protein does not appear
to be a substrate for calcineurin, it binds calcineurinstimulus.
At least one case of severe immunodeficiency was and inhibits its phosphatase activity. Thus PxIxIT-based
inhibitors might alter cellular balance by releasing activetraced to a defect in capacitative calcium entry that
was apparent in T and B cells as well as granulocytes, calcineurin from Cabin-1/Cain-1, presumably augment-
ing other calcineurin-dependent pathways while inhib-platelets, and fibroblasts (Le Deist et al., 1995). T cells
from this patient showed a severe reduction in NFAT iting NFAT. This possibility needs to be evaluated.
The PxIxIT motif may be part of a more extensiveactivation and pronounced defects in cytokine produc-
tion. The lack of reported cardiac dysfunction in this calcineurin-interacting surface of NFAT (Figure 2). Dele-
tion analysis of NFAT4 has suggested the existencepatient is noteworthy, given that calcium-dependent ac-
tivation of NFAT2 has been implicated in morphogenesis of additional calcineurin binding sites located at its N
terminus (Zhu and McKeon, 1999) and at the C terminusof cardiac valves (de la Pompa et al., 1998; Ranger et al.,
1998a). This phenotype might be due to a quantitative of its regulatory domain (Liu et al., 1999). These regions
are only partially conserved in the NFAT family. Furtherdefect in capacitative calcium entry, which permitted
normal valve development but was insufficient for im- work is necessary to establish whether they are part of
an extended calcineurin binding common to all NFATs,mune function; alternatively, the defect might lie in a
cell type±specific component of store-operated calcium or whether they constitute regions of interaction unique
to individual family members that might be targeted forentry. The latter possibility is particularly interesting for
immunosuppression. subtype-specific inhibition.
Dephosphorylation and Nuclear Import (3)Interaction of NFAT with Calcineurin (2)
Calcineurin binds to the NFAT regulatory domain, which In addition to the PxIxIT motif, the NFAT regulatory do-
main contains an extended serine-rich region (SRR), threeis located immediately N-terminal to the highly con-
served DNA binding domain (Figure 2). This regulatory serine- and proline-rich (ªSPº) sequence motifs with the
characteristic sequence SPxxSPxxSPxx[SPxx]xxx[D/E]domain is absent in NFAT5, consistent with its distinct
mode of regulation (Lopez-Rodriguez et al., 1999; Miya- [D/E], and a conserved nuclear localization signal (NLS)
located between the second and third ªSP motifsº (Fig-kawa et al., 1999). A major contributor to calcineurin
binding is a conserved sequence motif (PxIxIT) located ure 2). The regulatory domain is phosphorylated on ser-
ine residues in resting cells and dephosphorylated in aat the N terminus of the NFAT regulatory domain (Aram-
buru et al., 1998, 1999; Zhu et al., 1998). Peptides modeled calcineurin-dependent manner upon stimulation (Loh et al.,
1996b; Luo et al., 1996; Shibasaki et al., 1996). Dephos-on the PxIxIT motif inhibited the NFAT-calcineurin inter-
action and were markedly immunosuppressive when phorylation exposes the NFAT NLS, rendering it accessi-
ble to the machinery of nuclear import. The import recep-expressed in Jurkat T cells, inhibiting NFAT dephos-
phorylation, NFAT nuclear translocation, and PMA/iono- tors involved have not been identified but may include
the commonly utilized karyopherin (importin) a/b familymycin-induced expression of IL-2, IL-3, IL-13, TNFa,
GM-CSF, and MIP-1a mRNAs (Aramburu et al., 1998, that recognizes basic NLSs (Torgerson et al., 1998).
We have little specific information about the NFAT1999). However PxIxIT-based peptides did not inhibit
calcineurin phosphatase activity and therefore showed dephosphorylation/rephosphorylation cycle. Neither the
serine residues that are phosphorylated on endogenousgreater selectivity than CsA: for instance, they did not
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Figure 2. The NFAT Regulatory Domain
The conserved sequence motifs in the NFAT
family are shown as colored boxes and their
consensus sequences are indicated at the
bottom of the figure. Regions involved in reg-
ulating NFAT functions are indicated by thick
bars. Black bars indicate functional regions
that are conserved in multiple NFAT proteins,
while gray bars indicate regions whose func-
tions have been tested only in individual fam-
ily members or whose sequences are poorly
conserved in the NFAT family.
NFAT proteins in resting cells nor those that are lost has been suggested to release a potentially inhibitory
interaction between a serine-rich region in the regulatoryupon activation have been identified. While the presence
of conserved sequence motifs in the regulatory domain domain and a basic sequence in the DNA binding do-
main (Beals et al., 1997a). Although this interaction was(Figure 2) suggests regulatory mechanisms common to
all four NFATs, the low level of sequence identity (z30%) interpreted as controlling NFAT2 nuclear import, the ba-
sic sequence does not function as a required NLS insuggests the existence of unique (perhaps cell type±
specific) regulatory mechanisms as well. all NFAT proteins (Luo et al., 1996). Thus, it is equally
possible that the interaction regulates DNA binding. IfIn an attempt to identify phosphoserine residues
whose dephosphorylation might control nuclear import, so, inhibitors targeting this interaction might be useful,
since both interacting regions are conserved in the NFATNFAT2 and NFAT4 proteins with deletions and serine-
to-alanine mutations in the NFAT regulatory domain family and this mode of regulation may be common to
all four NFATs.have been tested. These experiments have yielded di-
vergent results (see Figure 2). In NFAT2, mutations in Calcineurin activity is continuously needed to main-
tain NFAT in the nucleus in a form with high affinity forall four conserved motifs (the serine-rich region and the
SP motifs) were shown to cause nuclear localization DNA (Loh et al., 1996a, 1996b; Shibasaki et al., 1996;
Timmerman et al., 1996). Two possible scenarios may(Beals et al., 1997a, 1997b). For NFAT4, the results were
less consistent: in one study, mutation of two residues be envisioned to explain this result; neither has yet been
tested experimentally. Calcineurin might be needed asin the serine-rich region of NFAT4 resulted in nuclear
localization (Chow et al., 1997), while in another report, an integral part of the NFAT transcriptional complex to
maintain NFAT in an active and dephosphorylated form,deletion of the entire serine-rich region rendered the
protein hypersensitive to calcium ionophore, a result particularly if DNA-bound NFAT present in active tran-
scriptional complexes is still capable of being inacti-interpreted by the authors as the effect of deleting the
docking site for CK1a, a proposed NFAT kinase (Zhu vated by rephosphorylation. Alternatively, the DNA-
bound, transcriptionally active fraction of NFAT mightet al., 1998; see below). The latter study located the
phosphoserine residues responsible for nuclear import not be accessible to calcineurin or nuclear kinases; if
so, the ongoing requirement for calcineurin indicatesin the first SP motif of NFAT4 (Zhu et al., 1998). While,
overall, the results implicate both the serine-rich region that this fraction of NFAT would be in continuous equilib-
rium with free nuclear NFAT. These possibilities are notand the SP motifs in regulating nuclear import, the spe-
cific discrepancies are puzzling given the high degree mutually exclusive: the detailed structure of NFAT-con-
taining transcriptional complexes is likely to vary de-of sequence conservation in the NFAT regulatory do-
main and the fact that all four NFATs are regulated by pending on the regulatory region involved, and hence
the accessibility of NFAT to modifying enzymes couldcalcineurin. These discrepancies will need to be re-
solved before pharmacological strategies targeting de- be different in each case.
Paradoxically, it has been suggested that calcineurinphosphorylation-regulated nuclear import can be de-
vised. activity is not necessary for transcription mediated by
NFAT2 and NFAT4 that have been artificially localized toDNA Binding and Transcriptional Activity (4)
In addition to nuclear import, calcineurin regulates the the nucleus (Timmerman et al., 1996; Zhu and McKeon,
1999). In both cases, constitutively nuclear mutant pro-DNA binding affinity of NFAT (Park et al., 1995; Shaw et
al., 1995). However, the precise mechanism involved has teins were used. The first report showed that constitu-
tively nuclear NFAT2 could be activated with PMA alonenot yet been elucidated. For NFAT2, dephosphorylation
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and concluded on this basis that calcineurin was re- NFAT and AP-1 (Fos/Jun) (Chen et al., 1998a). This inter-
action occurs on composite DNA sites of specific struc-quired only for nuclear entry (Timmerman et al., 1996).
ture and spacing, and the residues involved in the inter-In direct contrast, the second report showed that consti-
action are conserved in all NFATs. The highly conservedtutively nuclear NFAT4 was not transcriptionally active
E9F loop of NFAT, which makes major contacts with Junin PMA-stimulated cells but could be rendered active by
and DNA, is supported by a small hydrophobic patchcoexpression of either wild-type, constitutively active
that contains Phe473. Compounds that target the E9Fcalcineurin or a phosphatase-inactive version (Zhu and
loop or the hydrophobic pocket may selectively inhibitMcKeon, 1999). This study also showed that calcineurin
gene expression controlled by NFAT/Fos/Jun com-competed with the nuclear export receptor Crm1 for
plexes.binding to a nuclear export signal (NES) of NFAT4 and
GATA proteins constitute another common categorysuggested on this basis that calcineurin promoted the
of nuclear partners for NFAT. GATA2-NFAT2 interactiontranscriptional function of NFAT4 by interfering with ªfu-
was suggested based on coimmunoprecipitation oftile shuttling.º This function of calcineurin did not require
these two proteins and their coexpression in nuclei ofcalcineurin phosphatase activity. These disparate find-
differentiating myoblasts (Musaro et al., 1999), whereasings need to be resolved before the role of calcineurin
GATA4-NFAT3 interaction was observed in a yeast two-in regulating NFAT-mediated transcription can be un-
hybrid assay (Molkentin et al., 1998). Interactions involv-derstood and targeted pharmacologically.
ing GATA3 and NFAT have not yet been demonstrated,How might dephosphorylation regulate these multiple
but GATA3 and NFAT are both implicated in IL-5 genefunctions of NFAT? As shown for the yeast transcription
transcription (Rao et al., 1997; Zhang et al., 1997, 1999),factor Pho4 (Komeili and O'Shea 1999), the phosphoryla-
and targeting this interaction may be an effective waytion status of distinct residues (or clusters of residues)
of selectively inhibiting eosinophil function in atopy. Itmay control distinct functions of NFAT; alternatively, as
is not clear whether NFAT-GATA interactions, like theshown for retinoblastoma (Harbour et al., 1999), progres-
NFAT-AP-1 interaction, involve conserved regions insive changes in phosphorylation status may induce pro-
NFAT and GATA proteins, such that any NFAT proteingressive changes in the overall conformation of NFAT.
could potentially interact with any GATA protein if ex-A final possibility is that the phosphorylated form of
pressed in the same cell type at the same developmental
the NFAT regulatory domain possesses a repressive
stage. Alternatively, NFAT-GATA interactions could be
(masking) function, which is relieved by calcineurin-
constrained to individual members of the NFAT and
mediated dephosphorylation. By analogy with the estro-
GATA families, offering the possibility of selectively in-
gen receptor and other steroid hormone receptors, hibiting particular classes of target genes.
which repress the accessibility or function of adjacent Nuclear Export (6)
protein domains in their unliganded form but lose this Rephosphorylation of NFAT is accompanied by its nu-
repressive activity following ligand binding, the postu- clear export. Again, studies with NFAT2 and NFAT4 have
lated changes in the repressive function of the NFAT yielded somewhat discordant results. A nuclear export
regulatory domain may be mediated by differential inter- signal (NES) identified near the C terminus of the NFAT2
actions of its phosphorylated and dephosphorylated regulatory domain is fairly well conserved in NFAT1 but
forms with chaperones (Rutherford and Zuker, 1994). poorly conserved in NFAT3 and NFAT4; likewise, an NES
Do posttranslational modifications of NFAT contribute localized at the N terminus of NFAT4 is poorly conserved
to transcriptional activation? The transcriptional activity in NFAT1, 2, and 3 (Figure 2). The export receptor for
of NFAT is enhanced by binding to the nuclear coactiva- NFAT has been identified as Crm1 (Kehlenbach et al.,
tors p300 and CBP (Garcia-Rodriguez and Rao, 1998; 1998; Zhu and McKeon, 1999) based in part on the ability
Avots et al., 1999). The fraction of NFAT that is bound of the Crm1-binding compound leptomycin B to inhibit
to p300 in the nucleus shows an altered mobility in SDS NFAT nuclear export. Since Crm1 is involved in the nu-
gels (Garcia-Rodriguez and Rao, 1998), suggesting that clear export of multiple substrates (Pemberton et al.,
it might be posttranslationally modified by phosphoryla- 1998), it may not be useful to devise pharmacological
tion or acetylation. It is not known whether these (or strategies that target this export receptor. It should be
other) modifications are required for transcriptional borne in mind, however, that the import and export re-
function. If so, inhibition of the relevant nuclear modi- ceptors used in vivo may differ from those identified ex-
fying enzymes would be another way of suppressing perimentally. The interferon-induced transcription factor
NFAT activity, particularly if the enzymes were specific Stat1 uses a specialized import receptor in an unusual
for NFAT. By analogy with calcineurin, however, even mode of nuclear import (Sekimoto et al., 1997); likewise,
nonselective enzymes might be good targets for inhibi- the yeast transcription factor Pho4, which specifically
tion if they possessed a sufficiently limited range of regulates phosphate metabolism, uses dedicated im-
potential substrates. port and export receptors (Komeili and O'Shea, 1999).
DNA Binding and Interactions NFAT Kinases: Inactivation by Rephosphorylation (7)
with Partner Proteins (5) It is not yet clear whether NFAT rephosphorylation is
In the nucleus, NFAT binds to regulatory regions of its mediated by the same constitutively active kinases that
target genes. Optimal binding and transcriptional activa- maintain it in its inactive state in resting cells. The sub-
tion requires its incorporation into functional enhanceo- cellular distribution of such kinases is an important
some complexes, a process facilitated by cooperative point: they would need to be located in the nucleus to
binding with other transcription factors to DNA. A well- inactivate previously activated NFAT, and in the cyto-
plasm to maintain NFAT in its inactive form. Alternatively,characterized cooperative interaction is that between
Immunity
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NFAT may be inactivated by inducible kinases that be- it from DNA and favoring its nuclear export, while sup-
come activated and are present in the nucleus in stimu- pression of either constitutive or inducible kinases
lated cells. These possibilities are not mutually ex- would prolong NFAT activation by potentiating the effect
clusive. of calcineurin.
A total of four candidate NFAT kinasesÐtwo constitu- Summary
tive and two inducibleÐhave been identified to date In summary, several features of NFAT regulation are
(see Figure 2). (i) Glycogen synthase kinase-3 (GSK-3), promising in terms of immunosuppressive strategies.
which is constitutively active in differentiated cells but (i) Although capacitative calcium entry is a mechanism
is the target of the Wnt signaling pathway during devel- common to all cells, it may be regulated in part by cell
opment (Wodarz and Nusse, 1998), phosphorylates the type±specific mechanisms. Inhibitors that target such
conserved SP motifs of NFAT2 and promotes its nuclear mechanisms could be useful given the immunodefi-
export when overexpressed (Beals et al., 1997b). GSK-3 ciency phenotype discussed above. (ii) In light of the
has also been shown to phosphorylate NFAT3 and ac- potent inhibitory effects of PxIxIT-based peptides in cul-
celerate its nuclear export (Graef et al., 1999). For both tured cells, the NFAT-calcineurin interaction is a valid
NFAT2 and NFAT3, the extent of potentiation of nuclear and attractive target for immunosuppressive drugs. (iii)
export is approximately 3- to 4-fold. GSK-3 requires Hyperactivation of NFAT kinases required for nuclear
a priming kinase, and protein kinase A (which is not export would be expected to depress the immune re-
constitutively active) can fulfill this function in vitro, al- sponse. Unfortunately, the known candidates have bio-
though it does not appear to be the priming kinase in logical activities ranging well beyond NFAT and may not
vivo. Lithium, which inhibits several cellular enzymes be suitable pharmacological targets: dedicated NFAT
including GSK3, slowed by 2- to 3-fold the nuclear ex- kinases or nonselective kinases with a more limited
port of NFAT2 (Klemm et al., 1997; Kehlenbach et al., range of substrates are preferable if they exist. Also,
1998), apparently by inhibiting the release of NFAT2 more information is needed as to whether NFAT inactiva-
from DNA (Kehlenbach et al., 1998). (ii) Casein kinase tion is mediated by kinases that target all NFATs in
1a (CK1a) has been reported to be a major regulatory common or are specialized to act on individual NFATs.
kinase for NFAT4 (Zhu et al., 1998). Like GSK-3, CK1a (iv) It seems worthwhile to explore whether NFAT is
is constitutively active in resting cells. Overexpressed activated by posttranslational modifications in the nu-
CK1a slows, while kinase-inactive CK1a promotes, the cleus, since the enzymes involved would be highly at-
nuclear import of NFAT4. CK1a binds to a site in the tractive targets, especially if they were specific for one
serine-rich region of NFAT4 that is not fully conserved or more NFATs. (v) Targeting the interaction of NFAT
in the other NFATs but phosphorylates conserved resi- with nuclear partner proteins such as Fos/Jun and GATA
dues in the adjacent first SP motif. Thus, it remains to and nuclear coactivators such as p300 and CBP is also
be determined whether CK1a uniquely regulates NFAT4 an interesting option, since specialized regions of inter-
or is a common kinase for all members of the NFAT action will be used.
family. (iii) The MAP kinase kinase kinase MEKK1 has
been proposed to mediate the suppressive effects of
Would NFAT Inhibitors Be as Immunosuppressiveserum on NFAT dephosphorylation and nuclear translo-
as CsA or FK506?cation in cultured cells (Zhu et al., 1998). MEKK1 does
On the plus side of this equation, NFAT is known tonot phosphorylate NFAT4 directly but rather enhances
regulate a large number of genes required for immuneits association with CK1a in stimulated cells, perhaps by
function, and impairment of NFAT activation correlatesacting via an intermediate kinase. (iv) The Jun N-terminal
strongly with severe immune deficiency. On the minuskinase JNK2, a stress-activated MAP kinase that is acti-
side, calcineurin regulates several transcription factorsvated in cells exposed to UV or osmotic shock, has been
other than NFAT, which undoubtedly contribute to thereported to inhibit the nuclear accumulation of NFAT4
immune response, and certain cellular effects of CsAbut not of other NFAT proteins (Chow et al., 1997). This
and FK506 do not involve either calcineurin or NFAT.result contradicts a second report that found no effect
Finally, the cytokine TGFb has been suggested to medi-for the very similar enzyme JNK1 (Zhu et al., 1998). How-
ate both immunosuppressive and other effects of CsAever, T cells from JNK1-deficient mice showed in-
and FK506. These aspects are discussed individuallycreased nuclear accumulation of NFAT2 (but not NFAT1)
below (Figure 3).after stimulation, suggesting a selective roleÐdirect or
NFAT Regulates a Plethora of Genes EssentialindirectÐfor JNK1 in regulating NFAT2 (Dong et al.,
for Immune Function1998). These discrepancies need to be resolved.
NFAT is thought to regulate a large number of targetIn light of these data, it will be important to establish
genes expressed by activated immune cells, includingwhether NFAT rephosphorylation and inactivation is pri-
the cytokine genes IL-2, IL-3, IL-4, IL-5, IL-8, IL-13, GM-marily regulated by a common kinase capable of phos-
CSF, and IFNg; the cell surface receptors CD40L, FasL,phorylating all NFATs or by specific kinases that act on
and IL-2Ra (CD25) and the transcription factor EGR3 inindividual NFATs. Unfortunately, the candidate kinases
T cells; CD5 and Igk in B cells; IL-4, IL-5, and TNFa inhave in most cases been tested only with single NFAT
mast cells; and TNFa and GM-CSF in NK cells (reviewedproteins under conditions of significant overexpression
in Rao et al., 1997; for recent work see Latinis et al.,of both the kinase and NFAT. Compounds that target
1997; Berland and Wortis, 1998; Mages et al., 1998;NFAT kinases are likely to be useful immunomodulatory
Meyer and Ireland, 1998; Schuh et al., 1998a; Cron etagents once the questions of inducible versus constitu-
al., 1999). Expression of these genes meets three ortive kinases and specific versus common mechanisms
more of the following criteria for involvement of NFAT:of rephosphorylation are resolved. Activation of an in-
ducible kinase would render NFAT inactive by releasing (i) the genes are induced by signals that include calcium
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enzymes and transcription factors that are likely to con-
tribute to gene expression in activated immune cells
(Figure 3). (i) Calcineurin directly dephosphorylates and
inactivates the transcription factor Elk-1, a target of MAP
kinase pathways that regulates c-Fos gene transcription
(Sugimoto et al., 1997, 1998). (ii) Calcineurin regulates
NFkB activity in T cells, where it is implicated in IkB
kinase (IKK) activation, IkB degradation, and nuclear
appearance of NFkB p50, c-Rel, and RelA (Marienfeld
et al., 1997; Trushin et al., 1999). (iii) Calcineurin indirectly
modulates the activity of the transcription factor CREB
(Shaywitz and Greenberg, 1999). (iv) Calcineurin cooper-
ates with PKC-u to activate JNK, which phosphorylates
and activates the transcription factors c-Jun and ATF-2
(Werlen et al., 1998). (v) Calcineurin and JNK kinases
synergistically stablize IL-2 and IL-3 mRNAs in T cells
and mast cells respectively; CsA inhibits this stabiliza-
tion, a feature that may contribute to its immunosup-Figure 3. Multiple Pathways May Contribute to Immunosuppression
pressive effects (Chen et al., 1998b; Ming et al., 1998).Mediated by CsA and FK506
NFAT-based inhibitors would not be expected to targetA major component of the immunosuppressive effects of CsA and
these diverse processes in immune cells and so mightFK506 is the inhibition of calcineurin and its substrate NFAT (heavy
be less immunosuppressive than CsA and FK506.arrows). However, immunosuppression may also be effected
through inhibition of other calcineurin substrates or through in- Certain Cellular Effects of CsA and FK506 May Not
creases in TGFb levels. It is not yet known whether TGFb production Involve Calcineurin or NFAT
in response to CsA/FK506 is mediated through calcineurin or NFAT. CsA and/or FK506 influence the activity of certain tran-
scription factors in a manner independent of calcineurin
(Aramburu et al., 2000). The cyclophilin Cyp-40 binds
entry; (ii) their expression by activated cells is inhibited c-Myb and inhibits its DNA binding; this effect requires
by CsA; (iii) their promoter/enhancer regions contain the peptidyl-prolyl isomerase activity of Cyp-40 and is
specific binding sites for NFAT; (iv) in transient transfec- blocked by CsA (Leverson and Ness, 1998). In transient
reporter assays, CsA and FK506 also markedly potenti-tion assays, NFAT augments reporter activity driven by
ated transcription driven by ligand-activated glucocorti-these promoter/enhancer regions; and (v) when intro-
coid receptors (Renoir et al., 1995). When analogs ofduced into the reporter plasmid, mutations in the NFAT
CsA and FK506 were tested, potentiation did not corre-binding sites of the promoter/enhancer regions abolish
late either with calcineurin inhibition or with inhibition(or significantly diminish) reporter activity. The expres-
of the peptidyl-prolyl isomerase activities of cyclophilinssion of many of these same genes (IL-2, IL-3, IL-13, GM-
and FK506-binding proteins (FKBPs). Rather, the com-CSF, TNFa, MIP-1a) in T cells was inhibited by expres-
pounds were suggested to influence the function of glu-sion of a selective NFAT inhibitor, a high-affinity PxIxIT
cocorticoid receptor-containing complexes indirectlypeptide (Aramburu et al., 1999). In contrast, the PxIxIT
via binding to cyclophilin-40 and FKBP59 chaperonepeptide did not affect the induction of other CsA-sensi-
proteins present in the complexes (Rutherford andtive genes such as lymphotoxin-b or TNFb, which do
Zuker, 1994; Renoir et al., 1995). Again, NFAT-basednot fit the other criteria for involvement of NFAT.
inhibitors would not be expected to exhibit these func-Impairment of NFAT Activation Correlates
tions in immune cells.with Immune Deficiency
CsA and FK506 Augment TGFb ProductionAt least four cases of severe immunodeficiency have
Some of the immunosuppressive effects of CsA andbeen correlated with a marked impairment in the activa-
FK506 have been attributed to their ability to inducetion of NFAT (Castigli et al., 1993; Le Deist et al., 1995;
TGFb, a potent immunosuppressive cytokine, in various
Feske et al., 1996). The patients, who originated in three
cell types (Suthanthiran et al., 1996). The effects are
independent families, presented as infants with re- modest and somewhat variable but likely to be biologi-
peated infections and failure to thrive. In each case their cally significant. Stimulation of human peripheral blood
phenotype was traced to a syndrome of multiple cyto- T cells resulted in 1.5- to 4-fold increases in expression
kine deficiency. T cells from these patients were unable of TGFb mRNA and protein; supplementation of the cul-
to generate functional NFAT complexes but activated tures with CsA or FK506 augmented this increase by a
other transcription factors normally, and cytokine ex- further 1.5- to 5-fold (Li et al., 1991; Khanna et al., 1999b).
pression was profoundly impaired. The affected genes Increased TGFb levels were also reported in CsA-treated
(IL-2, IL-3, IL-4, IL-5, TNFa, and IFNg) are all potential patients awaiting renal transplantation (Shin et al., 1998),
NFAT target genes based on the criteria discussed although these results have been questioned (Hughes
above. et al., 1999).
Calcineurin Regulates Many Processes It remains to be determined whether the effects of
and Transcription Factors CsA on TGFb production are mediated through cal-
in Addition to NFAT cineurin and/or NFAT. Treatment of T cells or non-
As befits a highly conserved and ubiquitous enzyme, lymphoid cell lines with drug alone, in the absence of
calcineurin participates in many calcium-dependent stimulation, caused a significant increase in TGFb pro-
processes and has many substrates other than NFAT duction, suggesting a calcineurin-independent mecha-
nism operating in resting cells (Li et al., 1991; Khanna et al.,(Aramburu et al., 2000). Some of these involve signaling
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Figure 4. Comparison of the Toxic Effects of
CsA and FK506 with the Expression of NFAT
in Nonimmune Cells
On the left are shown the major side effects
of CsA and FK506, which may be indepen-
dent of calcineurin or due to inhibition of cal-
cineurin substrates other than NFAT. On the
right are shown some of the nonimmune tis-
sues reported to express NFAT. The compari-
son suggests that, overall, NFAT inhibitors
will have fewer side effects than CsA and
FK506. Note that the information on the left
is based on studies of CsA/FK506 toxicity in
humans, while most data on NFAT expression
and function (right) are derived from studies
in the mouse.
1999b). However, these results do not exclude additional (U.S. Multicenter FK506 study group, 1994; Mayer et al.,
calcineurin-dependent mechanisms in stimulated cells 1997). The nephrotoxicity occurs in two phases: an early
whereby CsA and FK506 counteract potential negative phase characterized by vasoconstriction and decreased
effects of calcineurin and/or NFAT on TGFb expression glomerular filtration rate, which progresses to interstitial
or gene transcription. Clearly, further experiments are tubular fibrosis, glomerular sclerosis, widespread vas-
needed. Note that TGFb has also been implicated in cular damage, and loss of functional nephrons (Myers,
some severe side effects of CsA and FK506Ðnephro- 1986; Pascual et al., 1998). CsA or FK506 treatment is
toxicity, hypertension, fibrosis, and tumor invasiveness also associated with an increased incidence of lympho-
(Pascual et al., 1998; Hojo et al., 1999; Khanna et al., mas and other malignancies, although this may be a
1999a, 1999b). general feature of long-term immunosuppression (Lon-
Summary don et al., 1995; Penn, 1987). TGFb produced in re-
In summary, NFAT seems likely to be a major target sponse to CsA/FK506 treatment is reported to cause
of CsA/FK506-induced immunosuppression given the increased tumor invasiveness (Hojo et al., 1999). The
severe phenotype of immunodeficiency patients im- molecular mechanisms underlying these diverse side
paired for NFAT activation and the large number of im- effects are poorly understood. While some of them are
mune genes that NFAT controls. However, some of the likely due to calcineurin inhibition, reflecting the ubiqui-
immunosuppression produced by CsA and FK506 could tous tissue distribution of calcineurin and its wide range
be mediated through TGFb, through calcineurin sub- of substrates, others have been suggested to be inde-
strates other than NFAT, or through various calcineurin- pendent of calcineurin. Below we outline the arguments
independent processes. To resolve this issue, it will be for involvement or noninvolvement of calcineurin in CsA/
necessary to compare directly the immunosuppressive FK506-induced toxicity, bearing in mind that these two
effects of selective NFAT inhibitors (e.g., PxIxIT-based scenarios are not mutually exclusive.
peptides) with those of CsA and FK506 in animal models Calcineurin-Dependent Toxicity
of immunosuppression. The best evidence in favor of calcineurin involvement
is that CsA and FK506 produce essentially the same
spectrum of toxic effects (US Multicenter FK506 studyWould NFAT Inhibitors Lack the Toxic Side Effects
group, 1994; Mayer et al., 1997). This observation pointsof CsA and FK506?
strongly to their common target calcineurin rather thanThe most common side effects of CsA and FK506 (Figure
to their immunophilin receptors, which are distinct. In-4) are nephrotoxicity, neurotoxicity (usually manifest as
deed, early studies with a panel of CsA and FK506 ana-seizures), tremor, insomnia, and headache; impaired
logs indicated that immunosuppression and nephrotox-glucose metabolism (hyperglycemia, diabetes); infec-
tions; gastrointestinal disturbances; and hypertension icity could not readily be separated: both effects
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correlated with inhibition of calcineurin but not peptidyl- The later phases of vascular damage in the kidney,
characterized by fibrosis, microangiopathy, and thick-prolyl isomerase activity, and all the nonimmunosup-
pressive analogs tested lacked nephrotoxic effects in ening of vessel walls, have been attributed to TGFb, a
cytokine believed to play a major role in CsA- and FK506-rodent and canine models (Sigal et al., 1991; Dumont et
al., 1992). induced nephrotoxicity (Myers, 1986; Pascual et al.,
1998). Mice treated with CsA showed increased TGFbCalcineurin, with its wealth of substrates, and NFAT,
with its many potential target genes in nonimmune cells, levels in the serum; increased renal expression of TGFb,
collagen and fibronectin mRNAs; and early histopatho-could both play a role in CsA/FK506-induced toxicity
(Figure 4). Calcineurin maintains cell function in multiple logical changes in the kidney (Khanna et al., 1999a).
These effects were all diminished by concurrent admin-ways: it modulates Ca21 responses by regulating inositol
trisphosphate (IP3) receptors, ryanodine receptors, NMDA istration of anti-TGFb antibody. As discussed in a previ-
ous section, it is unclear whether TGFb production isreceptors, and L-type Ca21 channels; regulates neu-
ronal, vascular, and smooth muscle function through mediated via calcineurin or NFAT.
Summaryeffects on nitric oxide (NO) synthases; regulates cellular
ion homeostasis through effects on Na1/K1 channels; In summary, it is unclear exactly what fraction of the
toxic effects of CsA and FK506 are mediated throughaffects vesicle recycling and neurotransmitter release
through amphiphysin and dynamin; and regulates cy- NFAT. However, NFAT-based immunosuppressants might
be predicted to have fewer and less severe side effectstoskeletal functions through the microtubule-associated
protein t (Drewes et al., 1993; Christopherson and Bredt, than CsA or FK506. This prediction could be tested
experimentally in animal models by comparing the toxic1997; Snyder et al., 1998; Aramburu et al., 2000). It is
plausible that long-term interference with these activi- side effects of selective NFAT inhibitors (such as PxIxIT-
based peptides) with those of CsA/FK506.ties would have an impact on the proper functioning of
organs such as the kidney, which plays a preeminent
role in ion homeostasis, or brain and muscle, which are Would NFAT Inhibitors Have Unexpected Side
tightly regulated by Ca21 and membrane polarization Effects in Immune or Nonimmune Cells?
(Figure 4). Likewise, NFAT and other calcineurin-depen- In this section, we consider the possibility that NFAT
dent transcription factors could regulate the expression inhibitors would have side effects that could not have
of proteins important for the normal function of those been predicted from our knowledge of CsA/FK506 toxic-
organs in which toxicity is observed. Indeed, as sug- ity. We briefly review the available information, obtained
gested for both NFAT2 and for the IP3 receptor, certain from targeted gene disruption, on the specific roles of
proteins that are posttranslationally regulated by cal- individual NFAT proteins in immune and nonimmune
cineurin could at the same time be transcriptional tar- cells (for a more extensive review see Viola and Rao,
gets for NFAT (Northrop et al., 1994; Snyder et al., 1998; 1999). It has been suggested that nonimmune cells are
Graef et al., 1999). relatively more resistant to CsA and FK506 than cells of
Calcineurin-Independent Toxicity the immune system because they express higher levels
A large number of the toxic effects of CsA and FK506 of calcineurin (Crabtree, 1999); if so, compounds that
directly targeted NFAT would be more effective than thehave been suggested to be independent of calcineurin.
However, this may simply reflect the complex nature of calcineurin inhibitors CsA and FK506 at inhibiting NFAT
functions in nonimmune cells. If this were the case, un-the damage, which even in the case of a single organ
may be due to many underlying processes. Thus, dys- expected side effects might be observed.
Immune Phenotypes of NFAT-Deficient Miceregulation of calcineurin substrates may initiate but may
not be involved in maintaining the sequence of events To date, the phenotypes of knockout mice lacking
NFAT1, NFAT2, NFAT4, and a double mutant lackingthat leads to clinically apparent organ damage. It should
also be borne in mind that the molecular processes NFAT1 and NFAT4 have been reported. Mutant mice
lacking individual NFAT family members show remark-thought to underlie toxicity have typically been studied
in cultured cells, and their relevance to the damage ably mild immune phenotypes, possibly because of their
redundant expression in immune cell types (Table 1).occurring in vivo is not always apparent.
To illustrate, the early renal vasoconstriction associ- Specifically, T cells deficient in NFAT2 show variable (2-
to 10-fold) impairment of IL-4 production, while T cellsated with CsA treatment has been related to the ability
of this drug to potentiate Ca21 influx in cultured vascular lacking NFAT1 tend to hyperproduce IL-4 (Hodge et al.,
1996; Kiani et al., 1997; Ranger et al., 1998b; Yoshida etsmooth cells stimulated with vasoconstrictor hormones
such as angiotensin II (Lo Russo et al., 1996; Avdonin al., 1998). As a result, NFAT12/2 mice display enhanced
allergic reactions and increased susceptibility to Leish-et al., 1999). This response was not immediate but re-
quired 20 hr of treatment with high doses of CsA. In mania infection in vivo (Hodge et al., 1996; Xanthoudakis
et al., 1996; Kiani et al., 1997; Viola et al., 1998). NFAT4-cell culture, the effect was at least partially calcineurin
independent, since CsA analogs that do not inhibit cal- deficient mice show a minor defect in thymocyte selec-
tion and no abnormality in cytokine production (Oukkacineurin, such as CsH, had similar but lesser effects.
However the cell culture findings did not correlate with et al., 1998). Surprisingly, however, the mild Th2 bias of
NFAT12/2 mice is dramatically enhanced in mice lackingnephrotoxic potential in vivo, since FK520, a potent im-
munosuppressant that is at least as toxic as CsA, did both NFAT1 and NFAT4, which suffer from severe spon-
taneous allergic reactions manifested as allergic blepha-not have the same effects. Thus, while calcineurin-inde-
pendent potentiation of calcium influx might contribute ritis, interstitial pneumonitis, and massive infiltration of
lymphoid organs with mast cells and eosinophils (Rangerto the renal damage induced by CsA in vivo, it does not
account for the very similar damage induced by FK506. et al., 1998c).
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T cells lacking NFAT2 also display mild defects in 1998; Symes et al., 1998; Armesilla et al., 1999; Furs-
tenau et al., 1999). NFAT1 is expressed in the olfactoryactivation and proliferation (Ranger et al., 1998b; Yo-
shida et al., 1998), whereas T cells lacking NFAT1 or bulb and shows limited expression in other areas of
the nervous system (Ho et al., 1994), while NFAT3 isNFAT4 (especially those obtained from older mice) ap-
pear preactivated or hyperactivated compared to wild- expressed in hippocampal neurons, where it can medi-
ate transactivation of an NFAT-dependent reporter genetype T cells (Oukka et al., 1998; Schuh et al., 1998b).
Again, this phenotype is exacerbated in mice doubly in response to depolarization (Graef et al., 1999). Regu-
lated expression and activation of NFAT proteins hasdeficient for NFAT1 and NFAT4: T cells from these mice
show massive hyperactivation, and the mice spontane- also been reported in skeletal muscle cells, vascular
smooth muscle cells, and a microglial cell line (Abbottously develop severe splenomegaly and lymphadenop-
athy (Ranger et al., 1998c). et al., 1998; Boss et al., 1998; Chin et al., 1998; Ferrari
et al., 1999; Musaro et al., 1999; Semsarian et al., 1999).While the mechanism underlying these effects is still
not understood at a molecular level, it is likely that all Summary
NFAT is clearly important in many cell types outside thethree NFAT proteins activate T cell proliferation and IL-4
expression, but only NFAT1 and NFAT4 are able to immune system, and its crucial role in cardiac valve
development would restrict the use of NFAT inhibitorsinduce negative-regulatory feedback mechanisms that
blunt proliferation and the late phase of IL-4 gene tran- during pregnancy. In adults, however, the role of NFAT
may be modulatory rather than essential, and chronicscription (Kiani et al., 1997). According to this model,
cells lacking NFAT1 and NFAT4 have completely lost the administration of NFAT inhibitors may be relatively in-
nocuous in a variety of conditions that call for immuno-feedback inhibitory mechanism but retain the positive
function of NFAT2. As a result, these cells become mas- suppression. Again, these predictions need to be tested
in appropriate animal models.sively hyperactivated and show an unusually prolonged
production of IL-4. In contrast, cells lacking NFAT2 are
mildly suppressed with respect to proliferation and IL-4 Looking Forward: Will NFAT-Based
production, presumably because the positive effects of Immunosuppression Play a Role
NFAT1 and NFAT4 are counteracted by the relative in- in the Future?
crease in their combined negative feedback effects. The most compelling argument in favor of NFAT-based
The nature of this postulated negative feedback immunosuppression is that the clinically valuable immu-
mechanism remains to be understood, since the inhibi- nosuppressants CsA and FK506 are already known to
tory gene products have not been identified. Conceiv- interfere with NFAT activation. As outlined at the end of
ably, these gene products could interfere with any step the section on NFAT regulation, several features of NFAT
of the signaling pathway leading to proliferation/IL-4 regulation are promising in terms of immunosuppressive
gene expression, including any of the steps of NFAT strategies. A good immunosuppressive agent will com-
activation itself (e.g., capacitative calcium entry, cal- bine efficacy with specificity, but specificity does not
cineurin activity, nuclear localization, etc.). In an extreme necessarily require the existence of regulatory proteins,
scenario, inhibition could be due to a late modification which are unique for NFAT. As exemplified by PxIxIT-
of NFAT1/NFAT4 by an inducible enzyme, a process based peptides for the NFAT-calcineurin interaction,
which might convert these proteins from transcriptional even abundant proteins (such as kinases, components
activators in the early stages to DNA-bound transcrip- of the nuclear import and export machinery, or nuclear
tional repressors in the late stage of the response. In partner proteins and cofactors) may be targeted, as long
any case, agents that interfere with NFAT function would as the interaction is relatively selective for NFAT and
be expected to inhibit not only the positive but also any amenable to pharmacological interference.
negative effects of NFAT proteins and so might have What Is the Likelihood that NFAT Inhibition Would
complex effects on the immune response. Have Undesired Side Effects?
Functions of NFAT in Nonimmune Cells This is an area in dire need of more specific information.
There is much evidence for NFAT expression and func- As discussed in previous sections, the contribution of
tion in cells outside the immune system. NFAT2-defi- NFAT to CsA and FK506 toxicity is not known. However,
cient mice die in utero because of defects in the morpho- patients treated with CsA or FK506 do not develop mus-
genesis of cardiac valves, thus demonstrating a vital cle dysfunction as a result of NFAT2 inhibition nor mem-
role for this protein in a limited subset of cells during a ory loss as a result of hippocampal NFAT3 inhibition.
very limited period of heart development (de la Pompa Likewise, the immunodeficiency patients in which all
et al., 1998; Ranger et al., 1998a). Overexpression of NFAT activation is impaired do not display the pheno-
either a constitutively nuclear form of the nonlymphoid types of knockout mice lacking individual or multiple
family member NFAT3 or an activated form of calcineurin NFAT proteins, nor do they show features associated
resulted in the development of cardiac hypertrophy in with CsA or FK506 toxicity. This is encouraging, because
transgenic mice (Molkentin et al., 1998). The ªclassicalº it suggests that the side effects of CsA and FK506 are
criteria noted previously have been used to implicate unrelated to NFAT inhibition in nonimmune cells.
NFAT in expression of the b-natriuretic peptide gene in There are two possibilities to explain these findings.
cardiomyocytes; the aP2 gene in adipocytes; the IL-3, One is that CsA and FK506 simply do not inhibit NFAT
GM-CSF, and tissue factor genes in endothelial cells; effectively in nonimmune cells, perhaps because nonim-
the glucagon gene in pancreatic islet cells; and the vaso- mune cells express higher levels of calcineurin than cells
active intestinal peptide gene in neuroblastoma cells of the immune system. If so, one would have to take
seriously the possibility that direct inhibitors of NFAT(Cockerill et al., 1995; Ho et al., 1998; Molkentin et al.,
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function would have a different spectrum of side effects Might It Be Useful to Develop Inhibitors
of Individual NFAT Proteins?from those of the calcineurin inhibitors CsA and FK506.
While the idea of targeting individual NFAT proteins isIn contrast if CsA and FK506 inhibit NFAT function as
attractive, current data suggest that this approach mighteffectively in nonimmune cells as in immune cells, the
be more deleterious in terms of immunosuppressionimplication would be that NFAT inhibition does not con-
than simply targeting all NFAT proteins. Balanced elimi-tribute in any major way to the side effects of these
nation of all NFAT function (as in the immunodeficientdrugs. This would in turn imply that NFAT plays a modu-
patients) correlates with severe suppression of immunelatory rather than a critical role in non-immune cell types.
function, while elimination of individual NFAT proteinsClearly, these possibilities could be resolved by directly
produces biologically significant biases in the immunecomparing the extent of NFAT inhibition in immune and
response (Table 1). The surprising inference from thesenonimmune cells of CsA/FK506-treated animals.
experiments is that individual NFATs in immune cellsAlthough PxIxIT-based peptides are not cell permeant
have largely redundant positive functions but their feed-and therefore cannot be used directly as pharmacologi-
back effects are nonredundant. Nevertheless, ªskew-cal agents in vivo, they are likely to be useful tools
ingº or ªredirectingº of the immune response rather thanwith which to evaluate both the utility and the potential
simple ªimmunosuppressionº is a fascinating potentialtoxicity of selective NFAT inhibition. Transgenic mice
extension of an NFAT-based targeting approach, as isexpressing these peptides in different tissues under in-
targeting of individual NFAT proteins in nonimmuneducible control may be used to test whether NFAT inhibi-
cells. Clinical situations where inhibition of an individualtors are sufficiently immunosuppressive in vivo, whether
family member may be useful include allergic asthmathey lack the toxicity of CsA and FK506, and whether
(NFAT2) and cardiac hypertrophy (NFAT3). The develop-they have unexpected side expects of their own. Indeed,
ment of such specific inhibitors will require a greatera transgenic mouse has been generated that expresses
appreciation of shared versus unique regulatory mecha-a ªdominant-negativeº NFAT, whose effectiveness is at
nisms, and shared versus unique functions, of individualleast partly due to inhibition of NFAT-calcineurin binding
NFAT proteins within and outside the immune system.(Chow et al., 1999). This mouse expresses 2-fold lower
levels of IL-2 in response to T cell stimulation but has
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